[Recombinant interleukin-2 (roncoleukin) in therapy of the patients with skin melanoma].
The article deals with a problem of combined use of interferon (laferon) and interleukin in patients with skin melanoma. Recombinant interleukin-2 (rIL-2) was included into the worked-out scheme. Patients with primary-localized skin melanoma (T(2-4)N0M0) have been studied. Three groups were chosen. 901 patients of the control group underwent excision of tumor (e/t); 34 patients of the first study group (e/1) were given endolymphatic interferontherapy (ift); 35 patients of the second study group were subjected to excision of tumor followed by endolymphatic interferontherapy. One-year relapse-free survival among patients of the control group reached 57.6+/-1.6%, 1st study group--70.5+/-7.8% and 2nd study group--83.6+/-6.7%. Total one-year survival among patients of the control group was 92.1+/-0.9%, in the 1st study group--97.0+/-2.9%, in the 2nd study group--92.7+/-5.0%. Thus, the combined use of recombinant interferon (laferon and interleukin (ronkoleukin) in treatment schemes of malignant skin melanoma was proved to be perspective.
Korovin
S I
SI
Tolstopiatov
B A
BA
Dovgopolaia
O A
OA
Palivets
A Iu
AIu
D000293:Adolescent; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use; D016898:Interferon-alpha; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery
D007370:Interferon Type I; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; C076799:interferon-alpha 8